clinical trial · NCT06467084
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
Hereditary AngioedemaKVD900 150 mgKVD900 300 mgKVD900 600 mg
brief summary
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
started
Jun 24, 2024
primary completion
Jan 15, 2026
completion
Jan 15, 2026
last updated
Jan 23, 2026
official title
Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With Hereditary Angioedema Type I or II
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol